Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Neuromuscular Blockade Reversal
NCT03579589Phase 1Completed
- Sponsor
- The Ohio State University
- Start
- Aug 2018
- Primary completion
- Dec 2019
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by The Ohio State University. Primary endpoint: Time from peritoneal closure to anesthesia readiness for OR discharge to PACU at 1 hour. Started Aug 2018; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03579589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579589.